ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ESSA Pharma Inc. Develops novel small molecule drugs to treat castration-resistant prostate cancer.	United States of America	EPIX
Estrella Immunopharma, Inc. Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.	United States of America	ESLA
Eton Pharmaceuticals, Inc. Develops and commercializes innovative treatments for rare pediatric diseases.	United States of America	ETON
EuBiologics Co., Ltd. Develops vaccines for global public health and provides biopharmaceutical CRMO services.	South Korea	206650
EUPRAXIA PHARMACEUTICALS INC. Developing targeted, extended-release therapies for GI and musculoskeletal diseases.	United States of America	EPRX
EuroAPI Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.	France	EAPI
Eurobio Scientific Develops & distributes specialty IVD tests for oncology, transplant & infectious diseases.	France	ALERS
European Institute of Science AB Manufactures diagnostic assays and point-of-care instruments for the veterinary health market.	Sweden	EURI B
Evoke Pharma Inc Develops and commercializes a nasal spray for diabetic gastroparesis symptom relief.	United States of America	EVOK
Evolus, Inc. Develops neurotoxins and dermal fillers for the medical aesthetics market.	United States of America	EOLS